Effect of Device Guided Breathing on Sleeplessness (2BRT01)

Sponsor
Afeka, The Tel-Aviv Academic College of Engineering (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02521324
Collaborator
Sheba Medical Center (Other)
0
1
2
20
0

Study Details

Study Description

Brief Summary

The current study is designed to evaluate the effect of device guided breathing (DGB) on sleeplessness. Healthy subjects with mild to moderate sleeplessness that wish to improve their sleep quality will be included in this study. The subjects will receive a belt type breathing sensor, download the app on their smartphone, and will be required to perform DGB at their home setting for 2 weeks after a baseline period.

Condition or Disease Intervention/Treatment Phase
  • Device: DGB2
N/A

Detailed Description

Sleeplessness, defined as difficulty in falling asleep or maintaining sleep, is prevalent in about one third of the US population. Sleeplessness was found to have negative impact on the quality of life and daily functionality and in its chronic form, was also found to frequently lead to sympathetic over-activity. Stress is an important factor in triggering and exacerbating sleeplessness and its symptoms.

Current methods for alleviating the problem include drugs, modification of sleep habits (also delivered via smartphones), cognitive behavior therapy that includes relaxation techniques such as mindfulness, meditation, and diaphragmatic breathing.

Breathing pattern modification, as done by Device Guided Breathing (DGB) was found to affect beneficially the cardiovascular system. DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing

Breathing pattern modification, as done by DGB was originally implemented in a device called RESPeRATE that was cleared by the FDA for treating hypertension and stress and its use was supported by multiple clinical trials. However, the direct effect of DGB on sleeplessness has not yet been investigated,

DGB was recently implemented in a mobile system that consists of a Bluetooth enabled belt-type breathing sensor and an iOS mobile application ('App'). The App accumulates continuously breathing-related data and performance measure. The accumulated data are sent to an icloud-based server.

The current study is a single center, prospective, randomized, waiting-list-controlled (WLC) clinical trial designed to evaluate the effect of DGB on sleeplessness using the mobile DGB2 system.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effect of Device-Guided Breathing on Healthy Subjects With Sleeplessness Using a Sensor and Mobile App
Anticipated Study Start Date :
May 1, 2018
Anticipated Primary Completion Date :
Dec 1, 2019
Anticipated Study Completion Date :
Jan 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Immediate treatment (IT)

Subjects from this group will perform 2 weeks of DGB with the DGB2 system immediately after 1 week of baseline monitoring. All subjects will answer questionnaires pertaining to their sleep quality.

Device: DGB2
DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .
Other Names:
  • Device Guided Breathing
  • Active Comparator: Wait list control (WLC)

    The subjects from the WLC group will do the same (answer questionnaires and perform 2 weeks of DGB with the DGB2 system) at a 1 week delay.

    Device: DGB2
    DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .
    Other Names:
  • Device Guided Breathing
  • Outcome Measures

    Primary Outcome Measures

    1. Change in Energetic/Fatigue visual analogue scale (VAS) from baseline to completion of 2 weeks of DGB [2 weeks]

    Secondary Outcome Measures

    1. Changes in sleep onset latency (SOL) from baseline to completion of 2 weeks of DGB [2 weeks]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Healthy with mild to moderate sleeplessness

    2. Male or Female, Age 18-65

    3. Has ipod/ipad or smartphone compatible with the system used in the study

    4. Has access to internet and email

    5. Knowledge of English to the level of understanding the App and the sleep-monitor interface.

    Exclusion Criteria:
    1. Known sleep or respiration disorder

    2. A serious systemic disease

    3. Pittsburg Insomnia Rating Scale (PIRS_2) <2

    4. Pregnant

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Afeka, Tel-Aviv Academic College of Engineering Tel-aviv Please Select Region, State Or Province Israel 65220

    Sponsors and Collaborators

    • Afeka, The Tel-Aviv Academic College of Engineering
    • Sheba Medical Center

    Investigators

    • Principal Investigator: Moshe Halak, MD, Sheba Medical Center
    • Study Director: Zehava Blechman, PhD, Afeka, Tel-Aviv Academic College of Engineering/

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Afeka, The Tel-Aviv Academic College of Engineering
    ClinicalTrials.gov Identifier:
    NCT02521324
    Other Study ID Numbers:
    • 2361-15-SMC
    First Posted:
    Aug 13, 2015
    Last Update Posted:
    Nov 16, 2021
    Last Verified:
    Nov 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 16, 2021